Cognitive ControlNCT03800030
Effect of Cross Frequency tACS on Cognitive Control
A study testing Theta-gamma tACS and Delta-beta tACS in people with Cognitive Control and Executive Function, run by University of North Carolina, Chapel Hill at 1 site in United States.
Trial summary
Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Control, Executive Function
- What is being tested?
- Theta-gamma tACS and Delta-beta tACS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 26 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Oct 2018to 25 Jul 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Between the ages of 18 and 35 years
- Able to provide informed consent
- Willing to comply with all study procedures and be available for the duration of the study Speak and understand English
Who cannot join
- Attention Deficit Hyperactivity Disorder (currently under treatment)
- Neurological disorders and conditions, including, but not limited to:
- History of epilepsy
- Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia
- History of stroke
- Parkinson's disease
Show all 17Show fewer
- Multiple sclerosis
- Cerebral aneurysm
- Brain tumors
- Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy)
- Prior brain surgery
- Any brain devices/implants, including cochlear implants and aneurysm clips
- History or current traumatic brain injury
- (For females) Pregnancy or breast feeding
- Personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.)
- Positive urine test for the following: Marijuana (THC), Cocaine (COC), Phencyclidine (PCP), Amphetamine (AMP), Ecstasy (MDMA), Methamphetamine (Mamp), Opiates (OPI), Oxycodone (OXY), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Tricyclic Antidepressants (TCA), Propoxyphene (PPX)
- Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
Trial locations and contacts
1 site in 1 country.
United States1 site
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599
About this study
Official title: A Pilot Study Investigating the Effects of Cross Frequency Transcranial Alternating Current Stimulation on Cortical Oscillations Underlying Cognition
Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex
Read the detailed description
Previous evidence suggests that there are specific frequency bands associated with different aspects of cognitive control. In specific delta (2-4Hz) and beta (15-30Hz) are associated with increased levels of abstraction for learned rules; and theta (5-8Hz) and gamma (30-50Hz) has been associated with increased set-size or number of learned rules. Here we aim to find causal evidence in support of these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tACS) in the specific frequency bands previously shown to be task-relevant. In a crossover design, we stimulate subjects with either delta-beta or theta-gamma tACS during performance of a hierarchical cognitive control task that manipulates the level of abstraction and set-size of rules that must be learned in order to make the correct button press.
- Conditions
- Cognitive Control, Executive Function
- Being tested
- Theta-gamma tACS, Delta-beta tACS, Sham tACS
- Keywords
- tACS, Cognitive Control, Executive Function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Theta-gamma tACSDevice
NeuroConn technologies, direct current-stimulator plus
Delta-beta tACSDevice
NeuroConn technologies, direct current-stimulator plus
Sham tACSDevice
NeuroConn technologies, direct current-stimulator plus
| Study group | Role | What they receive |
|---|---|---|
| Theta-gamma, Delta-beta, Sham | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
| Theta-gamma, Sham, Delta-beta | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
| Delta-beta, Theta-gamma, Sham tACS | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
| Delta-beta, Sham, Theta-gamma tACS | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
| Sham, Delta-beta, Theta-gamma tACS | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
| Sham, Theta-gamma, Delta-beta tACS | Experimental | Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS Receives: Device: Theta-gamma tACS; Device: Delta-beta tACS; Device: Sham tACS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reaction Time for Trials With High Abstraction Relative to Low Abstraction
For low abstraction conditions, subjects must memorize a color to button mapping. For high abstraction conditions, subject must make a perceptual judgement on the similarity of two objects based on either texture or shape as cued by a color. The reaction time difference between high and low abstraction conditions was hypothesized to decrease when delta-beta tACS was delivered. As a control for the placebo effect of stimulation, the difference between delta-beta tACS and sham tACS, or placebo, was used for statistical analysis.
Measured: through study completion, an average of 3 weeks
Reaction Time for Trials With High Set-size Relative to Low Set-size
The reaction time difference between high and low set-size conditions was hypothesized to decrease when theta-gamma tACS is delivered. As a control for the placebo effect of stimulation, the difference between theta-gamma tACS and sham tACS, or placebo, was used for statistical analysis.
Measured: through study completion, an average of 3 weeks
Delta Phase to Beta Amplitude Coupling Strength
Delta-beta tACS was hypothesized to increase cross frequency coupling strength (higher value) between the targeted frequency bands. Phase amplitude coupling between delta phase and beta amplitude was calculated for the two minute electrical brain recordings after stimulation. A null distribution was calculated by shuffling the beta amplitude time series relative to the delta phase time series and then calculating coupling strength. The outcome measure is the z-transformed value of the genuine phase amplitude coupling relative to the null distribution.
Measured: through study completion, an average of 3 weeks
Theta Phase to Gamma Amplitude Coupling Strength
Theta-gamma tACS was hypothesized to increase cross frequency coupling strength (higher value) between the targeted frequency bands. Phase amplitude coupling between theta phase and gamma amplitude was calculated for the two minute electrical brain recordings after stimulation. A null distribution was calculated by shuffling the gamma amplitude time series relative to the theta phase time series and then calculating coupling strength. The outcome measure is the z-transformed value of the genuine phase amplitude coupling relative to the null distribution.
Measured: through study completion, an average of 3 weeks
Percent Correct for Trials With High Abstraction Relative to Low Abstraction
For low abstraction conditions, subjects must memorize a color to button mapping. For high abstraction conditions, subject must make a perceptual judgement on the similarity of two objects based on either texture or shape as cued by a color. The accuracy difference between high and low abstraction conditions was hypothesized to decrease when delta-beta tACS was delivered. As a control for the placebo effect of stimulation, the difference between delta-beta tACS and sham tACS, or placebo, was used for statistical analysis.
Measured: through study completion, an average of 3 weeks
Percent Correct for Trials With High Set-size Relative to Low Set-size
The accuracy difference between high and low set-size conditions was hypothesized to decrease when theta-gamma tACS is delivered. As a control for the placebo effect of stimulation, the difference between theta-gamma tACS and sham tACS, or placebo, was used for statistical analysis.
Measured: through study completion, an average of 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2019
- Study start7 Oct 2018
- Primary completion25 Jul 2019
- Study completion25 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cognitive ControlStudies of the same condition, open and under way.
- More trials run by University of North Carolina, Chapel HillThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Healthy participants will receive three waveforms of transcranial alternating current stimulation (tACS). Delta-beta, Theta-gamma, and Sham.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Sponsor
- Investigators
- Flavio Frohlich, PhD, Principal investigator, University of North Carolina, Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03800030
- Sponsor's protocol ID
- 18-0003
- Other IDs
- R01MH101547
- Status last verified
- Sep 2019
- First submitted
- 18 Dec 2018
- Last updated
- 18 May 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Riddle J, McFerren A, Frohlich F. Causal role of cross-frequency coupling in distinct components of cognitive control. Prog Neurobiol. 2021 Jul;202:102033. doi: 10.1016/j.pneurobio.2021.102033. Epub 2021 Mar 16.
PubMed 33741402
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Study Investigating the Effects of Cross Frequency Transcranial Alternating Current Stimulation on Cortical Oscillations Underlying Cognition
- ClinicalTrials.gov ID
- NCT03800030
- Acronym / sponsor ID
- 18-0003
- Conditions
- Cognitive Control, Executive Function
- Keywords
- tACS, Cognitive Control, Executive Function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- 7 Oct 2018 (actual)
- Primary completion
- 25 Jul 2019 (actual)
- Study completion
- 25 Jul 2019 (actual)
- First posted
- 10 Jan 2019 (actual)
- Results
- Posted 18 May 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex
Detailed description
Previous evidence suggests that there are specific frequency bands associated with different aspects of cognitive control. In specific delta (2-4Hz) and beta (15-30Hz) are associated with increased levels of abstraction for learned rules; and theta (5-8Hz) and gamma (30-50Hz) has been associated with increased set-size or number of learned rules. Here we aim to find causal evidence in support of these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tACS) in the specific frequency bands previously shown to be task-relevant. In a crossover design, we stimulate subjects with either delta-beta or theta-gamma tACS during performance of a hierarchical cognitive control task that manipulates the level of abstraction and set-size of rules that must be learned in order to make the correct button press.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
- Model description
- Healthy participants will receive three waveforms of transcranial alternating current stimulation (tACS). Delta-beta, Theta-gamma, and Sham.
| Arm | Type | Receives |
|---|---|---|
| Theta-gamma, Delta-beta, Sham | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS |
| Theta-gamma, Sham, Delta-beta | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS |
| Delta-beta, Theta-gamma, Sham tACS | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS |
| Delta-beta, Sham, Theta-gamma tACS | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS |
| Sham, Delta-beta, Theta-gamma tACS | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS |
| Sham, Theta-gamma, Delta-beta tACS | Experimental | Device: Theta-gamma tACS, Device: Delta-beta tACS, Device: Sham tACSEvery participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task. Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Between the ages of 18 and 35 years
- Able to provide informed consent
- Willing to comply with all study procedures and be available for the duration of the study Speak and understand English
Key exclusion criteria (17 listed)
- Attention Deficit Hyperactivity Disorder (currently under treatment)
- Neurological disorders and conditions, including, but not limited to:
- History of epilepsy
- Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia
- History of stroke
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Theta-gamma tACSNeuroConn technologies, direct current-stimulator plus | Device | Delta-beta, Sham, Theta-gamma tACS, Delta-beta, Theta-gamma, Sham tACS, Sham, Delta-beta, Theta-gamma tACS, Sham, Theta-gamma, Delta-beta tACS, Theta-gamma, Delta-beta, Sham, Theta-gamma, Sham, Delta-beta |
| Delta-beta tACSNeuroConn technologies, direct current-stimulator plus | Device | Delta-beta, Sham, Theta-gamma tACS, Delta-beta, Theta-gamma, Sham tACS, Sham, Delta-beta, Theta-gamma tACS, Sham, Theta-gamma, Delta-beta tACS, Theta-gamma, Delta-beta, Sham, Theta-gamma, Sham, Delta-beta |
| Sham tACSNeuroConn technologies, direct current-stimulator plus | Device | Delta-beta, Sham, Theta-gamma tACS, Delta-beta, Theta-gamma, Sham tACS, Sham, Delta-beta, Theta-gamma tACS, Sham, Theta-gamma, Delta-beta tACS, Theta-gamma, Delta-beta, Sham, Theta-gamma, Sham, Delta-beta |
Primary outcome
Reaction Time for Trials With High Abstraction Relative to Low Abstraction
Time frame: through study completion, an average of 3 weeks
For low abstraction conditions, subjects must memorize a color to button mapping. For high abstraction conditions, subject must make a perceptual judgement on the similarity of two objects based on either texture or shape as cued by a color. The reaction time difference between high and low abstraction conditions was hypothesized to decrease when delta-beta tACS was delivered. As a control for the placebo effect of stimulation, the difference between delta-beta tACS and sham tACS, or placebo, was used for statistical analysis.
Reaction Time for Trials With High Set-size Relative to Low Set-size
Time frame: through study completion, an average of 3 weeks
The reaction time difference between high and low set-size conditions was hypothesized to decrease when theta-gamma tACS is delivered. As a control for the placebo effect of stimulation, the difference between theta-gamma tACS and sham tACS, or placebo, was used for statistical analysis.
Delta Phase to Beta Amplitude Coupling Strength
Time frame: through study completion, an average of 3 weeks
Delta-beta tACS was hypothesized to increase cross frequency coupling strength (higher value) between the targeted frequency bands. Phase amplitude coupling between delta phase and beta amplitude was calculated for the two minute electrical brain recordings after stimulation. A null distribution was calculated by shuffling the beta amplitude time series relative to the delta phase time series and then calculating coupling strength. The outcome measure is the z-transformed value of the genuine phase amplitude coupling relative to the null distribution.
Theta Phase to Gamma Amplitude Coupling Strength
Time frame: through study completion, an average of 3 weeks
Theta-gamma tACS was hypothesized to increase cross frequency coupling strength (higher value) between the targeted frequency bands. Phase amplitude coupling between theta phase and gamma amplitude was calculated for the two minute electrical brain recordings after stimulation. A null distribution was calculated by shuffling the gamma amplitude time series relative to the theta phase time series and then calculating coupling strength. The outcome measure is the z-transformed value of the genuine phase amplitude coupling relative to the null distribution.
Percent Correct for Trials With High Abstraction Relative to Low Abstraction
Time frame: through study completion, an average of 3 weeks
For low abstraction conditions, subjects must memorize a color to button mapping. For high abstraction conditions, subject must make a perceptual judgement on the similarity of two objects based on either texture or shape as cued by a color. The accuracy difference between high and low abstraction conditions was hypothesized to decrease when delta-beta tACS was delivered. As a control for the placebo effect of stimulation, the difference between delta-beta tACS and sham tACS, or placebo, was used for statistical analysis.
Percent Correct for Trials With High Set-size Relative to Low Set-size
Time frame: through study completion, an average of 3 weeks
The accuracy difference between high and low set-size conditions was hypothesized to decrease when theta-gamma tACS is delivered. As a control for the placebo effect of stimulation, the difference between theta-gamma tACS and sham tACS, or placebo, was used for statistical analysis.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33741402Riddle J, McFerren A, Frohlich F. Causal role of cross-frequency coupling in distinct components of cognitive control. Prog Neurobiol. 2021 Jul;202:102033. doi: 10.1016/j.pneurobio.2021.102033. Epub 2021 Mar 16.
- Individual participant dataSharing planned: No
Related trials for Cognitive Control
Not yet recruiting
Cognitive-Motor Training With the DextEgg in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
Active, not recruiting
Effects of Individualized Preferred and Higher Treadmill Walking Speeds Followed by Cognitive Training on Heart Rate Variability, Gait Performance, and Motor-Cognitive Function in Older Adults With Type 2 Diabetes: A Randomized Controlled Trial With 4-Week Retention Follow-up
Diabetes Mellitus, Type 2
RecruitingObservational study
Motor Development and Early Predictors of Psychomotor Outcomes in Preterm and Term Infants Assessed by MOS-R and Caregiver Questionnaire at 18 and 36 Months
Neurodevelopmental Disorders, Motor Skills Disorders
Recruiting
IMST for Dementia Risk Reduction
Systolic Blood Pressure, Blood Pressure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Flavio Frohlich, PhD principal investigator
University of North Carolina, Chapel Hill
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Theta-gamma tACS and Delta-beta tACS in people with Cognitive Control and Executive Function, run by University of North Carolina, Chapel Hill at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reaction Time for Trials With High Abstraction Relative to Low Abstraction (time frame: through study completion, an average of 3 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03800030, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2020.